- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00896571
Transdermal Contraceptive Patch - Endometrial Effects Study
November 24, 2014 updated by: Bayer
Single-center,Open-label, Uncontrolled Study to Investigate the Effects of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene on the Endometrium in a 21-day Regimen for 13 Cycles in 80 Healthy Women
The aim of the present study is to investigate the effects of the transdermal patch on the endometrium in healthy women who require contraception.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
92
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10629
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Requiring contraception
- Normal cervical smear
- Smokers not older than 30 years
- History of regular cyclic menstrual periods
Exclusion Criteria:
- Pregnancy or lactation
- Obesity (BMI> 30 kg/m2)
- Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape
- Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
- Use of other contraceptive methods than study medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
|
7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effect on the endometrium at cycle 13
Time Frame: 13 treatment cycles (each consisting of 28 days)
|
13 treatment cycles (each consisting of 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cervical smear
Time Frame: 13 treatment cycles (each consisting of 28 days)
|
13 treatment cycles (each consisting of 28 days)
|
Adverse events
Time Frame: 13 treatment cycles (each consisting of 28 days)
|
13 treatment cycles (each consisting of 28 days)
|
Cycle control
Time Frame: 13 treatment cycles (each consisting of 28 days)
|
13 treatment cycles (each consisting of 28 days)
|
Safety laboratory
Time Frame: 13 treatment cycles (each consisting of 28 days)
|
13 treatment cycles (each consisting of 28 days)
|
Occurence of pregnancy
Time Frame: 13 treatment cycles (each consisting of 28 days)
|
13 treatment cycles (each consisting of 28 days)
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Treatment compliance
Time Frame: 13 treatment cycles (each consisting of 28 days)
|
13 treatment cycles (each consisting of 28 days)
|
Subjective assessment of satisfaction with the treatment
Time Frame: 13 treatment cycles (each consisting of 28 days)
|
13 treatment cycles (each consisting of 28 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
May 8, 2009
First Submitted That Met QC Criteria
May 8, 2009
First Posted (Estimate)
May 11, 2009
Study Record Updates
Last Update Posted (Estimate)
November 26, 2014
Last Update Submitted That Met QC Criteria
November 24, 2014
Last Verified
November 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14287
- 2009-010599-45 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ); Essential Access HealthNot yet recruitingContraception | Contraception Behavior | Reproductive BehaviorUnited States
Clinical Trials on Ethinylestradiol/Gestogene (BAY86-5016)
-
BayerParexelCompleted
-
BayerCompletedContraceptionItaly, Spain, Australia, France, Germany, Argentina, Mexico, Chile
-
BayerTerminatedContraception | Ovulation InhibitionGermany
-
BayerCompletedContraception | Ovulation InhibitionGermany
-
BayerCompleted
-
BayerCompletedContraceptionUnited States
-
BayerCompletedContraceptionGermany
-
BayerCompleted